

JAN

				
IDEAL ST.	PATENT AND TRADEMARK	COFFICE		
INFORMATION	N DISCLOSURE STATEMENT	Docket Number: 1662/63303		
Application Number	Filing Date	Examiner	Art Unit	
10/802,627	March 17, 2004	Susannah E.	1626	
		Lee		
Invention Title		Inventor(s) RUKHMAN, et al.		
POLYMORPHS O	F VALSARTAN			

Address to

Mail Stop: Amendments Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendments

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on

Signature:

Sir:

- 1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue there from. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
- 2. Copies of each patent, publication or other information listed on the modified PTO Form No. 1449 are enclosed, except as otherwise specified.
- 3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge deposit account number 11-0600 for such fees. A duplicate of this communication is enclosed for charging purposes.

Dated: 50- 30,06

By:

Payam Moradian (Reg. No. 52048)

KENYON & KENYON LLP

One Broadway

New York, N.Y. 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

CUSTOMER NO. 26646



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449

ATTY. DOCKET NO.	SERIAL NO.
1662/63303	10/802,627
APPLICANT RUKHMAN et al.	
FILING DATE	GROUP
March 17, 2004	1626

U. S. PATENT DOCUMENTS

	EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
Г							

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
· · · · · · · · · · · · · · · · · · ·						YES	NO
	EP 0443983 B1	February 12, 1991	EPO				
	00570091 A1	February 24, 1993	EPO				
	WO 01/82858 A2	November 8, 2001	PCT				
-	WO 01/82858 A3	November 8, 2001	PCT				
•	WO 02/06253 A1	January 24, 2002	PCT				
,	WO 03/070246 A1	August 28, 2003	PCT				
	WO 03/089417 A1	October 30, 2003	PCT				
	WO 2004/026847 A1	April 1, 2004	PCT				
	WO 2004/094392 A1	November 4, 2004	PCT				
	WO 97/30036	August 21, 1997	PCT				
	WO 99/01459	January 14, 1999	PCT				
	WO 99/67231	December 29, 2999	PCT				
	WO 2005/089720 A1	September 29 2005	PCT			1	1

OTHER DOCUMENTS

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Buhlmayer, Peter, et al., Valsartan, A Potent, Orally Active Angiotensin II Antagonist Developed From The Structurally New Amino Acid Series, Bioorganic & Medical Chemistry Letters, 1994, Vol. 4, No. 1, pp. 29-34.
	Borka, Laszlo, Crystal Polymorphism of Pharmaceuticals, Acta Pharmaceutica Jugoslavica, 1990, pp. 71-94.
·	Moenius, Th., et al., Carbon-14 Labelling of Diovan™ in its Valine-Moiety, Journal of Labelled Compounds and Radiopharmaceuticals, 2000, Vol. 43, pp. 1245-1252.
	Zhong Guo, et al. Chinese Journal of Pharmaceuticals, 2002, Vol. 32 Part 9, pp. 385-387.
	The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 1996, pp. 1691.

EXAMINER	DATE CONSIDERED			
•				
	<u> </u>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and				
not considered. Include copy of this form with next communication to applicant.				